Commerce Bank Takes $926,000 Position in Elanco Animal Health Incorporated $ELAN

Commerce Bank purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 37,614 shares of the company’s stock, valued at approximately $926,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ELAN. NewEdge Advisors LLC grew its stake in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Elanco Animal Health during the second quarter worth $38,000. Root Financial Partners LLC increased its holdings in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health in the 4th quarter valued at $41,000. Finally, Torren Management LLC bought a new position in shares of Elanco Animal Health in the 4th quarter valued at $46,000. 97.48% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of research reports. UBS Group boosted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Citigroup increased their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley lifted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. TD Cowen boosted their price target on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Finally, Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.09.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $25.09 on Thursday. The firm has a market cap of $12.54 billion, a P/E ratio of -61.20, a P/E/G ratio of 1.50 and a beta of 1.67. The business has a fifty day simple moving average of $24.61 and a 200 day simple moving average of $24.01. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period last year, the company earned $0.26 earnings per share. The firm’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Insider Activity

In other news, Director Paul Herendeen purchased 10,000 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were purchased at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the transaction, the director owned 111,687 shares of the company’s stock, valued at approximately $2,644,748.16. This trade represents a 9.83% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Lawrence Erik Kurzius acquired 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The stock was purchased at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the purchase, the director owned 188,647 shares in the company, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.